Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Beacon Pointe Advisors LLC

Beacon Pointe Advisors LLC trimmed its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 3.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 207,321 shares of the biopharmaceutical company's stock after selling 7,300 shares during the period. Beacon Pointe Advisors LLC's holdings in Bristol-Myers Squibb were worth $11,726,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of BMY. Morse Asset Management Inc lifted its stake in shares of Bristol-Myers Squibb by 25.0% in the 3rd quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company's stock valued at $517,000 after purchasing an additional 2,000 shares during the last quarter. Tudor Financial Inc. bought a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at approximately $250,000. Pine Valley Investments Ltd Liability Co lifted its stake in shares of Bristol-Myers Squibb by 1.3% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 44,897 shares of the biopharmaceutical company's stock valued at $2,323,000 after purchasing an additional 575 shares during the last quarter. World Investment Advisors LLC lifted its stake in shares of Bristol-Myers Squibb by 18.7% in the 3rd quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company's stock valued at $2,282,000 after purchasing an additional 6,954 shares during the last quarter. Finally, Arvest Bank Trust Division bought a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at approximately $1,724,000. 76.41% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were bought at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the acquisition, the executive vice president now owns 63,932 shares in the company, valued at $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Stock Performance

BMY stock traded down $0.67 during midday trading on Thursday, reaching $49.53. The stock had a trading volume of 17,161,789 shares, compared to its average volume of 12,973,691. The firm has a fifty day simple moving average of $55.99 and a two-hundred day simple moving average of $56.41. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The stock has a market cap of $100.79 billion, a PE ratio of -11.21, a P/E/G ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company's revenue was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($4.40) earnings per share. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be issued a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 5.01%. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on BMY shares. Wells Fargo & Company raised their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. UBS Group decreased their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Argus raised Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Citigroup raised their price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.